These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 26598593)

  • 21. Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion.
    Arias HR; Santamaría A; Ali SF
    Int Rev Neurobiol; 2009; 88():223-55. PubMed ID: 19897080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dopaminergic mediation of the discriminative stimulus effects of bupropion in rats.
    Terry P; Katz JL
    Psychopharmacology (Berl); 1997 Nov; 134(2):201-12. PubMed ID: 9399385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bupropion abuse resulting in hypomania in a geriatric amphetamine user: A case report.
    Rostas A; Wolf U
    Am J Addict; 2015 Dec; 24(8):765-6. PubMed ID: 26587916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Successful treatment of depression in a Parkinson disease patient with bupropion].
    Leentjens AF; Verhey FR; Vreeling FW
    Ned Tijdschr Geneeskd; 2000 Nov; 144(45):2157-9. PubMed ID: 11086491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The antidepressant bupropion is a negative allosteric modulator of serotonin type 3A receptors.
    Pandhare A; Pappu AS; Wilms H; Blanton MP; Jansen M
    Neuropharmacology; 2017 Feb; 113(Pt A):89-99. PubMed ID: 27671323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bupropion Hydrochloride Sustained Release and Diurnal Enuresis: A Previously Unreported Adverse Effect.
    Schwitalla TA; Patel RA; Catalano G; Nirmalani-Gandhy A
    Clin Neuropharmacol; 2019; 42(6):211-213. PubMed ID: 31644430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice.
    Brustolim D; Ribeiro-dos-Santos R; Kast RE; Altschuler EL; Soares MB
    Int Immunopharmacol; 2006 Jun; 6(6):903-7. PubMed ID: 16644475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments.
    Raskin S; Durst R
    Med Hypotheses; 2010 Dec; 75(6):544-6. PubMed ID: 20708340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum sickness induced by bupropion.
    Yolles JC; Armenta WA; Alao AO
    Ann Pharmacother; 1999 Sep; 33(9):931-3. PubMed ID: 10492492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of dopamine receptors by bupropion: comparison with antidepressants and CNS stimulants.
    Vassout A; Bruinink A; Krauss J; Waldmeier P; Bischoff S
    J Recept Res; 1993; 13(1-4):341-54. PubMed ID: 8095555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review of bupropion.
    Bryant SG; Guernsey BG; Ingrim NB
    Clin Pharm; 1983; 2(6):525-37. PubMed ID: 6140095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How does bupropion work as a smoking cessation aid?
    Warner C; Shoaib M
    Addict Biol; 2005 Sep; 10(3):219-31. PubMed ID: 16109583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A case of treating cathinone dependence and comorbid depression using bupropion.
    Lev-Ran S
    J Psychoactive Drugs; 2012; 44(5):434-6. PubMed ID: 23457895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant.
    Patel K; Allen S; Haque MN; Angelescu I; Baumeister D; Tracy DK
    Ther Adv Psychopharmacol; 2016 Apr; 6(2):99-144. PubMed ID: 27141292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors.
    Damaj MI; Carroll FI; Eaton JB; Navarro HA; Blough BE; Mirza S; Lukas RJ; Martin BR
    Mol Pharmacol; 2004 Sep; 66(3):675-82. PubMed ID: 15322260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aphthous ulcers associated with bupropion in a female adolescent: a case verified by rechallenge.
    Chiang CK; Chou YH; Chen YH; Sha CB; Liang CS
    Gen Hosp Psychiatry; 2011; 33(4):411.e1-2. PubMed ID: 21762840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Refractory depression with catatonic features was remitted with administration of intravenous dopamine and consequent bupropion as maintenance treatment.
    Liu YW; Chang C; Chen TY; Chang HA; Kao YC; Tzeng NS
    Aust N Z J Psychiatry; 2016 Jun; 50(6):599. PubMed ID: 26560841
    [No Abstract]   [Full Text] [Related]  

  • 38. Bupropion SR reduces periodic limb movements associated with arousals from sleep in depressed patients with periodic limb movement disorder.
    Nofzinger EA; Fasiczka A; Berman S; Thase ME
    J Clin Psychiatry; 2000 Nov; 61(11):858-62. PubMed ID: 11105739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of bupropion on hippocampal neurotransmitters and on peripheral hormonal concentrations in the rat.
    Piacentini MF; Clinckers R; Meeusen R; Sarre S; Ebinger G; Michotte Y
    J Appl Physiol (1985); 2003 Aug; 95(2):652-6. PubMed ID: 12692144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous bupropion: a previously undocumented method of abuse of a commonly prescribed antidepressant agent.
    Baribeau D; Araki KF
    J Addict Med; 2013; 7(3):216-7. PubMed ID: 23519045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.